1cP-MiPLA
 |
This page has not been fully approved by the PsychonautWiki administrators. It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards. |
| Summary sheet: 1cP-MiPLA |
| 1cP-MiPLA | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
|||||||||||||||||||||||||||||||
| Chemical Nomenclature | |||||||||||||||||||||||||||||||
| Common names | 1cP-MiPLA | ||||||||||||||||||||||||||||||
| Substitutive name | 1-Cyclopropionylmethylisoproyllysergamide | ||||||||||||||||||||||||||||||
| Systematic name | (6aR,9R)1-Cyclopropionyl-N-methyl-N-isopropyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide | ||||||||||||||||||||||||||||||
| Class Membership | |||||||||||||||||||||||||||||||
| Psychoactive class | Psychedelic | ||||||||||||||||||||||||||||||
| Chemical class | Lysergamide | ||||||||||||||||||||||||||||||
| Routes of Administration | |||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
| Interactions | |||||||||||||||||||||||||||||||
| Cannabis | |||||||||||||||||||||||||||||||
| Stimulants | |||||||||||||||||||||||||||||||
| Tramadol | |||||||||||||||||||||||||||||||
| Lithium | |||||||||||||||||||||||||||||||
1-Cyclopropionyl-N-methyl-N-isopropyllysergamide (also known commonly as 1cP-MiPLA) is a novel psychedelic substance of the lysergamide class. 1cP-MiPLA is closely related to MiPLA, for which it is suspected to be a prodrug for, but there is currently no data or enough anecdotal reports to reasonably hypothesize this.
1cP-MiPLA is a novel research chemical which seems to have appeared first in 2020 or 2021, allegedly first synthesized by either Skyler Ulrich or a chemist/group under the name of Gerstmann[citation needed], alongside other novel lysergamides like 1cP-AL-LAD on various research chemical markets.
User reports describe the effects of 1cP-MiPLA as similar to those of MiPLA. Some anecdotal reports state that there could be a notable, if even slight, difference between the two although this does not indicate that that it isn't a true prodrug for MiPLA. Many effects seem to be identical or nearly identical.
Very little data exists about the pharmacological properties, metabolism, and toxicity of 1cP-MiPLA. While it is often characterized by users as being generally more recreational and non-threatening compared to LSD, it is highly advised to approach this highly potent hallucinogenic substance with the proper amount of precaution and harm reduction practices if using it.
Chemistry
1cP-MiPLA, or 1-Cyclopropionyl-N-methyl-N-isopropyllysergamide, is a semisynthetic alkaloid of the lysergamide family. 1cP-MiPLA is a structural analog of lysergic acid, with an N-methyl-N-isopropylamide functional group bound to RN of the chemical structure.
1cP-MiPLA's chemical structure contains a bicyclic hexahydroindole fused to a bicyclic quinoline group (nor-lysergic acid). It is substituted at R1 with a Cyclopropionyl substituent. At carbon 8 of the quinoline a N,N-diethyl carboxamide is bound.
1cP-MiPLA is a chiral compound with two stereocenters at R5 and R8. 1cP-MiPLA, also called (+)-D-1cP-MiPLA , has an absolute configuration of (5R, 8R). The three other stereoisomers of 1cP-MiPLA presumably do not have psychoactive properties.[citation needed]
Pharmacology
1cP-MiPLA likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from 1cP-MiPLA's efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain an object of scientific elucidation.
1cP-MiPLA is also suspected to be a prodrug for MiPLA, given it's 1-Cyclopropionyl substitution. This can be compared with 1cP-LSD, which is also likely a prodrug for LSD. However there is not enough data, anecdotes or guaratees that this will be the exact same property of 1cP-MiPLA.
1cP-MiPLA also shares many common traits with its parent compound LSD; in humans it appears to be roughly equal (or less) in potency as well as similar in mechanism although the progression and duration of effects are compressed (while remaining qualitatively less intense and more manageable - perhaps due to being catabolised more readily). It is also notably less potent.
Subjective effects
While its subjective effects largely overlap with those of MiPLA and less so LSD, 1cP-MiPLA is commonly reported to be significantly shorter in its duration and less uncomfortable in both its negative physical side effects and general anxiety.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Physical effects 
-
- Stimulation - Similar to LSD, 1cP-MiPLA is considered to be primarily stimulating in nature. This is in distinction to other, more commonly used psychedelics such as psilocybin which are more consistent in producing sedation and relaxedness.
- Spontaneous bodily sensations - The "body high" of 1cP-MiPLA can be described as proportionally intense in comparison to its accompanying visual and cognitive effects. It behaves as a pleasurable, fast-moving, sharp and location specific tingling sensation. For some, it is manifested spontaneously at different unpredictable points throughout the experience, but for most it maintains a steady presence that rises with the onset and hits its limit once the peak has been reached. In comparison to LSD, 1cP-MiPLA is a little less sharp in the tingling sensations it produces as but is otherwise essentially indistinguishable.
- Physical euphoria - Physical euphoria on 1cP-MiPLA is not as consistent as it is with substances like stimulants or entactogens, and can just as easily manifest as physical discomfort without any apparent reason.
- Changes in felt bodily form - This effect is often accompanied by a sense of warmth or unity and usually occurs during and up to the peak of the experience or directly afterward. Users can feel as if they are physically part of or conjoined with other objects. This is usually reported as feeling comfortable and peaceful in its sensations.
- Tactile enhancement - Feelings of enhanced tactile sensations are consistently present at moderate levels throughout most 1cP-MiPLA trips.
- Temperature regulation suppression[citation needed]
- Increased bodily temperature[citation needed]
- Nausea
- Stamina enhancement - Generally mild in comparison to traditional stimulants.
- Bodily control enhancement
- Appetite suppression
- Difficulty urinating
- Increased blood pressure[citation needed]
- Increased heart rate[citation needed]
- Increased perspiration
- Muscle contractions
- Muscle spasms
- Increased libido
- Excessive yawning - This effect is significantly less pronounced than it is with psilocybin and its related compounds, the four-position substituted tryptamines.
- Pupil dilation
- Increased salivation
- Seizure[citation needed] - The possibility of seizures is extrapolated from the seizures that have been reported following the use of LSD. They are thought to mainly be a risk in those who are genetically predisposed to them, particularly while accompanied by physically taxing conditions such as dehydration, fatigue or undernourishment.
Visual effects 
-
Enhancements
Distortions
- Drifting (melting, breathing, morphing and flowing) - In comparison to other psychedelics, this effect can be described as highly detailed yet cartoon-like in appearance. The distortions are slow and smooth in motion and fleeting in their appearance. This is nearly identical in appearance to the visual drifting which occurs under the influence of LSD.
- After images
- Tracers
- Colour shifting
- Depth perception distortions
- Diffraction
- Scenery slicing
- Symmetrical texture repetition
Geometry
The visual geometry evoked by 1cP-MiPLA can be described as more similar in appearance to that of LSD, 2C-B or 4-HO-MET than psilocin, LSA or DMT. It can be comprehensively described through its variations as primarily intricate in complexity, algorithmic in form, unstructured in organization, brightly lit, colourful and cartoonish in scheme, organic in feel, flat in shading, soft in its edges, large in size, slow in speed, smooth in motion, either angular or round in its corners, non-immersive in-depth and consistent in intensity. At higher dosages, it consistently results in states of Level 8B visual geometry over Level 8A.
In comparison to LSD specifically, 1cP-MiPLA's geometry tends to be more rounded in its corners, slightly softer in its edges, warmer in hue, and slightly less intricate in its form. Aside from this, it is otherwise identical in its appearance.
Hallucinatory states
1cP-MiPLA is capable of producing a full range of low and high level hallucinatory states in a fashion that is a less consistent and reproducible than that of many other commonly used psychedelics such as psilocin or DMT but considerably more likely to when compared to that of LSD. This can feel similar to the hallucinations which occur with 4-AcO-DMT but tends to occur almost exclusively at heavier doses. Some of these effects include:
- Machinescapes
- Transformations
- Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - This effect is very consistent in dark environments at appropriately high dosages. They can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and occasionally of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
- External hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots)
Cognitive effects 
-
- Analysis enhancement - This effect is consistent in its manifestation and outrospection dominant.
- Conceptual thinking
- Cognitive euphoria
- Novelty enhancement
- Immersion enhancement
- Focus enhancement - This effect is experienced exclusively on low or threshold dosages and feels less forced than it does with stimulants.
- Immersion enhancement
- Motivation enhancement
- Emotion enhancement
- Increased music appreciation
- Increased sense of humor
- Memory suppression
- Time distortion
- Déjà vu
- Delusion
- Thought acceleration
- Thought loops
- Wakefulness
Auditory effects 
Transpersonal effects 
- Reports indicate that the transpersonal effects of 1cP-MiPLA are comparatively weaker than those of LSD and other lysergamides, as well as classical psychedelics such as psilocybin mushrooms or mescaline.
Combination effects
- Alcohol - Alcohol's central depressant effects can counteract some of the anxiety and bodily tension produced by 1cP-MiPLA. However, alcohol can cause dehydration, nausea and physical fatigue which can negatively impact the tone of the trip. Users are advised to pace themselves and drink a portion of their usual amount.
- Benzodiazepines - Benzodiazepines are highly effective at reducing the intensity of 1cP-MiPLA's effects through the general suppression of brain activity.
- Cannabis - Cannabis strongly intensifies the sensory and cognitive effects of 1cP-MiPLA. Extreme caution is advised when using this combination as it can significantly increase the chances of a negative psychological reaction like anxiety, confusion and psychosis. Users are advised to start off with only a fraction of their usual cannabis dose and take long breaks between hits to avoid over intake.
- Dissociatives - 1cP-MiPLA enhances the cognitive, visual and general hallucinatory effects of dissociatives. Dissociative-induced holes, spaces, and voids and internal hallucinations become more vivid and intense on 1cP-MiPLA. These effects correspond with an increased risk of confusion, delusions, and psychosis.
- MDMA - 1cP-MiPLA and MDMA are highly synergistic and mutually enhance each other's physical, cognitive, and visual effects. The synergy between these substances is unpredictable so it is advised to start with markedly lower doses than one would take for each individually. There is some evidence that suggests that co-administration of LSD with MDMA increases the neurotoxicity of the latter,[1][2][3] and this may extend to 1cP-MiPLA.
Experience reports
There are currently 0 anecdotal reports which describe the effects of this compound within our experience index.
Toxicity and harm potential
 |
This toxicity and harm potential section is a stub. As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it. |
The toxicity and long-term health effects of recreational 1cP-MiPLA use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 1cP-MiPLA is a research chemical with very little history of human usage.
The body of anecdotal reports suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
As with other psychedelic substances, there are relatively few physical side effects that have been reported associated with acute 1cP-MiPLA exposure. Although no formal studies have been conducted, it is likely that as with LSD itself, 1cP-MiPLA is able to be considered non-addictive, with an extremely low toxicity relative to dose.[4] It is also likely that as with LSD, there are little to no negative physical, cognitive, psychiatric or other toxic consequences associated with acute 1cP-MiPLA exposure.
However, as with LSD and psychedelics in general, it is possible that 1cP-MiPLA can act as a potential trigger for those with underlying psychiatric conditions. Those with a personal or family history of mental illness are generally advised not to use this substance, particularly outside of a supervised medical setting.
It is strongly recommended that one uses harm reduction practices when using this substance.
Dependence and abuse potential
Although no formal studies have been conducted, it is not unreasonable to assume that as with LSD itself, 1cP-MiPLA is not habit-forming and that the desire to use it can actually decrease with use.
Tolerance to the effects of 1cP-MiPLA is built almost immediately after ingestion. After that, it takes about 5-7 days for the tolerance to be reduced to half and 14 days to be back at baseline (in the absence of further consumption). 1cP-MiPLA presents cross-tolerance with all psychedelics, meaning that after the use of 1cP-MiPLA all psychedelics will have a reduced effect.
Overdose
The LD50 of 1cP-MiPLA is unknown. Adverse psychological reactions are common especially at higher dosages. Some of these include anxiety, delusions, panic attacks and more rarely seizures. Medical attention is usually only needed if suspected of severe psychotic episodes or “fake acid” (such as 25i-NBOMe or DOB). Administration of benzodiazepines or antipsychotics can help to relieve the negative cognitive effects of 1cP-MiPLA.
Dangerous interactions
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
- Lithium - Lithium is commonly prescribed for the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
- Cannabis - Cannabis may have an unexpectedly strong and unpredictable synergy with the effects of 1cP-MiPLA. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid unintentional overdose.
- Stimulants - Stimulants like amphetamine, cocaine or methylphenidate affect many parts of the brain and alter dopaminergic function. This combination can increase the risk of anxiety, paranoia, panic attacks, and thought loops. This interaction may also result in an elevated risk of mania and psychosis.[citation needed]
- Tramadol - Tramadol is well-documented to lower the seizure threshold[5] and psychedelics may act to trigger seizures in susceptible individuals.[citation needed]
Legal status
1cP-MiPLA is currently a gray area compound within many parts of the world. This means that it is not known to be specifically illegal within most countries, but people may still be charged for its possession under certain circumstances such as under analog laws and with the intent to sell or consume.
- Austria: 1cP-MiPLA is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.[citation needed]
- Germany: 1cP-MiPLA is illegal in Germany as of July 2021.[citation needed]
- Switzerland: 1cP-MiPLA can be considered a controlled substance as a defined derivative of Lysergic Acid under Verzeichnis E point 263. It is legal when used for scientific or industrial use.[6]
- United States: 1cP-MiPLA is unscheduled but can be considered to be an analogue of LSD, which would make it illegal to possess for human consumption under the Federal Analogue Act.[citation needed]
See also
External links
References
- ↑ Armstrong, B. D.; Paik, E.; Chhith, S.; Lelievre, V.; Waschek, J. A.; Howard, S. G. (2004). "Potentiation of (DL)‐3,4‐methylenedioxymethamphetamine (MDMA)‐induced toxicity by the serotonin 2A receptior partial agonist d‐lysergic acid diethylamide (LSD), and the protection of same by the serotonin 2A/2C receptor antagonist MDL 11,939". Neuroscience Research Communications. 35 (2): 83–95. doi:10.1002/nrc.20023. ISSN 1520-6769.
- ↑ Gudelsky, Gary A.; Yamamoto, Bryan; Nash, J. Frank (1994). "Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists". European Journal of Pharmacology. 264 (3): 325–330. doi:10.1016/0014-2999(94)90669-6. ISSN 0014-2999.
- ↑ Capela, J. P.; Fernandes, E.; Remião, F.; Bastos, M. L.; Meisel, A.; Carvalho, F. (2007). "Ecstasy induces apoptosis via 5-HT2A-receptor stimulation in cortical neurons". Neurotoxicology. 28 (4): 868–875. doi:10.1016/j.neuro.2007.04.005. ISSN 0161-813X. PMID 17572501.
- ↑ Passie, T.; Halpern, J. H.; Stichtenoth, D. O.; Emrich, H. M.; Hintzen, A. "The Pharmacology of Lysergic Acid Diethylamide: A Review" (PDF). CNS Neuroscience & Therapeutics. 14: 295–314. doi:10.1111/j.1755-5949.2008.00059.x. ISSN 1755-5930. Archived from the original (PDF) on May 1, 2013. Retrieved January 1, 2020.
- ↑ Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039.
- ↑ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel,psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien: Änderung vom 2. November 2015" (PDF) (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.